

National Cancer Institute

Technology Transfer Branch (TTB)

About TTB:

The National Cancer Institute's (NCI) Technology Transfer Branch recognizes that interactions with researchers outside the National Institutes of Health (NIH) can play an important role in helping you achieve research goals. Whether your interactions involve collaborating on a research project or simply obtaining research materials unavailable at NIH, complex intellectual property issues are often involved. TTB supports your scientific efforts by negotiating agreements between the NIH and outside organizations to ensure that the necessary agreements satisfy both your research objectives and NIH's intellectual property policy. At TTB, we handle not only the day-to-day negotiations, but all other aspects of the agreement process, so you can spend less time on paperwork and

For Further Information

TTB has two locations. Staff serving the Bethesda/Rockville area are located at the Rockville Office. Staff serving the NCI Frederick Cancer Research and Development Center are located at the Frederick Office.

National Cancer Institute
Technology Transfer Branch
6120 Executive Blvd., Suite 450
Rockville, MD 20852
Telephone: (301) 496-0477
Fax: (301) 402-2117

National Cancer Institute
Technology Transfer Branch
Frederick Cancer Research and Development Center
1003 W. 7th Street, Suite 502
Frederick, MD 21702
Telephone: (301) 846-5465
Fax: (301) 846-6820

e-mail: outreach@otd.nci.nih.gov
web site: <http://ttb.nci.nih.gov>



August 1999



TECHNOLOGY TRANSFER BRANCH

BUILDING

SUCCESSFUL RESEARCH

PARTNERSHIPS

CRADA

MTA

CDA

CTA

more time on research.

**NATIONAL INSTITUTES
OF HEALTH**
National Cancer Institute

TTB Supporting Collaborative Research

Benefits of Collaborative Research

Collaborating with organizations outside the NIH can bring numerous benefits to your laboratory. For example, under a Cooperative Research and Development Agreement (CRADA), your laboratory may have access to personnel, services, facilities, and equipment that are not available at NIH. Being involved in a CRADA project also allows you to continue to influence the direction of the research, as you and leading industrial scientists take your laboratory findings the next step closer to commercialization.



Laser Capture

Services of TTB

TTB negotiates for you the following collaborative agreements:

- **Cooperative Research and Development Agreement (CRADA)**– Fostering collaborative research with outside organizations which can provide your laboratory with personnel, services, facilities and equipment.
- **Material Transfer Agreement (MTA)**– Helping you obtain research materials from outside organizations.
- **Confidential Disclosure Agreement (CDA)**– Providing for the free exchange of confidential research information with an outside party while ensuring control over public disclosure.
- **Clinical Trials Agreement (CTA)**– Facilitating the transfer of research materials from outside parties for use in

We've Got Your Lab Covered

It's easy to obtain TTB's services. A small team of TTB staff members has been assigned to your laboratory to handle all your negotiation and intellectual property needs. Our staff includes professionals with expertise in diverse areas such as molecular biology, pharmacology and law. The staff members assigned to your lab will provide advice and guidance, negotiate agreements for you, answer questions and keep you informed throughout the process so that your time is spent on research and not on paperwork. To find out which TTB staff members have been assigned to your laboratory, please contact TTB using the information on the back cover or visit our web site at <http://ttb.nci.nih.gov>.

Microdissection (LCM), which allows the clinician to microdissect out cellular elements of interest during the diagnosis and treatment of cancer, is the subject of a CRADA with Arcturus Engineering. Now widely used in over 150 labs worldwide, LCM has been instrumental to the Cancer Genome Anatomy Project, with over 20,000 new genes found. The PixCell™ LCM System and Imaging Archiving Workstation, and CapSure™ Transfer Film are now commercially available products.

NCI-sponsored clinical trials.

And There's More...

Additional Services of TTB:

- **Marketing**– Promoting your technologies to outside organizations in order to foster research collaborations.
- **Advice on intellectual property issues**– Providing advice on the development and management of intellectual property, such as inventorship, patent protection and royalty income.
- **Education**– Keeping you posted on the latest developments in technology development and transfer.



Taxol®, among the most active anticancer agents discovered in 20 years, was clinically developed under a CRADA with Bristol-Myers Squibb (BMS). By the CRADA's end, over 29,000 patients had been treated, and three inventions patented and licensed. As a result of the efforts of both NCI and BMS, FDA approvals have been obtained for five indications, including refractory ovarian and breast cancers.